Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme.
Loutfy
Mona
M
Maple Leaf Medical Clinic, Toronto, Canada.
Ribera
Esteban
E
Florence
Eric
E
De Wit
Stéphane
S
Castagna
Antonella
A
Ryan
Robert
R
Hill
Andrew
A
Vanaken
Hilde
H
van Delft
Yvonne
Y
Marks
Stephan
S
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D000077560:Enfuvirtide; D005260:Female; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D010446:Peptide Fragments / Q000627:therapeutic use*; D010865:Pilot Projects; D011724:Pyridazines / Q000627:therapeutic use*; D011743:Pyrimidines; D012367:RNA, Viral / Q000097:blood*; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D009570:Nitriles; D010446:Peptide Fragments; D011724:Pyridazines; D011743:Pyrimidines; D012367:RNA, Viral; C451734:etravirine; D000077560:Enfuvirtide